-
1
-
-
84892637595
-
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: A single institution series
-
Rosenberg JD, Burian C, Waalen J, Saven A. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single institution series. Blood. 2014;123(2):177-183
-
(2014)
Blood
, vol.123
, Issue.2
, pp. 177-183
-
-
Rosenberg, J.D.1
Burian, C.2
Waalen, J.3
Saven, A.4
-
3
-
-
0025274664
-
Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
-
Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322(16):1117-1121 (Pubitemid 20149529)
-
(1990)
New England Journal of Medicine
, vol.322
, Issue.16
, pp. 1117-1121
-
-
Piro, L.D.1
Carrera, C.J.2
Carson, D.A.3
Beutler, E.4
-
4
-
-
79959293462
-
BRAF mutations in hairy-cell leukemia
-
Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011; 364(24):2305-2315
-
(2011)
N Engl J Med
, vol.364
, Issue.24
, pp. 2305-2315
-
-
Tiacci, E.1
Trifonov, V.2
Schiavoni, G.3
-
5
-
-
79957455041
-
Insight into the behavior of hairy cell leukemia by immunogenetic analysis
-
Forconi F, Cencini E, Sozzi E, Sicuranza A, Raspadori D, Lauria F. Insight into the behavior of hairy cell leukemia by immunogenetic analysis. Leuk Lymphoma. 2011;52(suppl 2):103-107
-
(2011)
Leuk Lymphoma
, vol.52
, Issue.SUPPL. 2
, pp. 103-107
-
-
Forconi, F.1
Cencini, E.2
Sozzi, E.3
Sicuranza, A.4
Raspadori, D.5
Lauria, F.6
-
6
-
-
84859576293
-
Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
-
Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330-3332
-
(2012)
Blood
, vol.119
, Issue.14
, pp. 3330-3332
-
-
Xi, L.1
Arons, E.2
Navarro, W.3
-
7
-
-
84861542159
-
Phase i trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
-
Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822-1828
-
(2012)
J Clin Oncol
, vol.30
, Issue.15
, pp. 1822-1828
-
-
Kreitman, R.J.1
Tallman, M.S.2
Robak, T.3
-
8
-
-
84861417677
-
BRAF inhibition in refractory hairy-cell leukemia
-
Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366(21): 2038-2040
-
(2012)
N Engl J Med
, vol.366
, Issue.21
, pp. 2038-2040
-
-
Dietrich, S.1
Glimm, H.2
Andrulis, M.3
Von Kalle, C.4
Ho, A.D.5
Zenz, T.6
-
9
-
-
79952091306
-
Modern strategies for hairy cell leukemia
-
Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol. 2011;29(5):583-590
-
(2011)
J Clin Oncol
, vol.29
, Issue.5
, pp. 583-590
-
-
Grever, M.R.1
Lozanski, G.2
-
10
-
-
79957521362
-
The microenvironment in hairy cell leukemia: Pathways and potential therapeutic targets
-
Burger JA, Sivina M, Ravandi F. The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leuk Lymphoma. 2011; 52(suppl 2):94-98
-
(2011)
Leuk Lymphoma
, vol.52
, Issue.SUPPL. 2
, pp. 94-98
-
-
Burger, J.A.1
Sivina, M.2
Ravandi, F.3
|